Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

v3.21.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Shareholder's Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2019 $ 28,930 $ 80,169,724 $ (53,045,782) $ (27,152,872) $ 27,152,872
Balance, shares at Sep. 30, 2019 28,930,493          
Issuance of common stock upon exercise of warrants $ 1,061 (955) 106 106
Issuance of common stock upon exercise of warrants, shares 1,060,615          
Issuance of common stock for services $ 187 99,813 100,000 100,000
Issuance of common stock for services, shares 186,566          
Stock-based compensation expense 220,384 220,384 220,384
Net loss (4,322,370) (4,322,370) (4,322,370)
Balance at Dec. 31, 2019 $ 30,178 80,488,966 (57,368,152) 23,150,992 23,150,992
Balance, shares at Dec. 31, 2019 30,177,674          
Issuance of common stock upon exercise of warrants $ 7,614 6,019,417 6,027,031 6,027,031
Issuance of common stock upon exercise of warrants, shares 7,614,388          
Issuance of common stock for services $ 286 305,734 306,020 306,020
Issuance of common stock for services, shares 286,000          
Stock-based compensation expense 158,833 158,833 158,833
Net loss (4,424,969) (4,424,969) (4,424,969)
Balance at Mar. 31, 2020 $ 38,078 86,972,950 (61,793,121) 25,217,907 25,217,907
Balance, shares at Mar. 31, 2020 38,078,062          
Balance at Sep. 30, 2020 $ 55,577 104,208,958 (70,593,867) 33,670,668 33,670,668
Balance, shares at Sep. 30, 2020 55,576,996          
Issuance of NoveCite common stock 1,799,640 (2,399,520) (599,880) 600,380 500
Stock-based compensation expense 276,582 276,582 276,582
Net loss (8,146,909) (8,146,909) (8,146,909)
Balance at Dec. 31, 2020 $ 55,577 106,285,180 (81,140,296) 25,200,461 600,380 25,800,841
Balance, shares at Dec. 31, 2020 55,576,996          
Issuance of common stock in private placement offering $ 15,456 18,434,954 18,450,410 18,450,410
Issuance of common stock in private placement offering, shares 15,455,960          
Issuance of common stock in registered direct offering $ 50,830 70,929,012 70,979,842 70,979,842
Issuance of common stock in registered direct offering, shares 50,830,566          
Issuance of common stock upon exercise of warrants $ 12,788 14,229,755 14,242,543 14,242,543
Issuance of common stock upon exercise of warrants, shares 12,787,697          
Issuance of common stock for services $ 50 67,950 68,000 68,000
Issuance of common stock for services, shares 50,000          
Stock-based compensation expense 342,962 342,962 342,962
Net loss (4,122,432) (4,122,432) (4,122,432)
Balance at Mar. 31, 2021 $ 134,701 $ 210,289,813 $ (85,262,728) $ 125,161,786 $ 600,380 $ 125,762,166
Balance, shares at Mar. 31, 2021 134,701,219